1227934-69-1

Basic information

• Product Name: ETHYL 2-BROMO-4-(TRIFLUOROMETHYL)OXAZOLE-5-CARBOXYLATE
• Synonyms: ETHYL 2-BROMO-4-(TRIFLUOROMETHYL)OXAZOLE-5-CARBOXYLATE;Ethyl 2-bromo-4-(trifluoromethyl)oxazole-5-carboxylat
• CAS NO: 1227934-69-1
• Molecular Formula: C₇H₅BrF₃NO₃
• Molecular Weight: 288.0187096
• Mol File: 1227934-69-1.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 297.5±50.0 °C(Predicted)
• Appearance: /
• Density: 1.698±0.06 g/cm3(Predicted)
• PKA: -6.06±0.10(Predicted)
• CAS DataBase Reference: ETHYL 2-BROMO-4-(TRIFLUOROMETHYL)OXAZOLE-5-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 2-BROMO-4-(TRIFLUOROMETHYL)OXAZOLE-5-CARBOXYLATE(1227934-69-1)
• EPA Substance Registry System: ETHYL 2-BROMO-4-(TRIFLUOROMETHYL)OXAZOLE-5-CARBOXYLATE(1227934-69-1)

Safety Data

• Hazardous Substances Data: 1227934-69-1(Hazardous Substances Data)

Upstream product

• 135026-17-4 ethyl 2-amino-4-(trifluoromethyl)oxazole-5-carboxylate 
• 363-58-6 ethyl 2-chloro-4,4,4-trifluoro-3-oxobutanoate 

Downstream Products

• 1227935-01-4 ethyl 2-(cyclohexylthio)-4-trifluoromethyloxazole-5-carboxylate 
• 1227934-99-7 2-(cyclohexyl(methyl)amino)-4-trifluoromethyloxazole-5-carboxylic acid 
• 1227934-89-5 2-(4-phenylpiperidin-1-yl)-4-trifluoromethyloxazole-5-carboxylic acid 
• 1227935-02-5 2-(cyclohexylthio)-4-trifluoromethyloxazole-5-carboxylic acid 
• 1227934-64-6 Cyclopentyl 4-[5-(2-(cyclohexylthio)-4-(trifluoromethyl)oxazole-5-carboxamido)pyridin-2-yl]piperazine-1-carboxylate 

Relevant articles and documents

THERAPEUTIC INHIBITORY COMPOUNDS

Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting plasma kallikrein. Furthermore, the subject compounds and compositions are useful for the treatment of diseases wherein the inhibition of plasma kallikrein inhibition has been implicated, such as angioedema and the like.

INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE

The present invention relates to novel heterocyclic compounds as diacylglycerol acyltransferase ("DGAT") inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. An illustrative compound of the invention is shown below.